The Selection of Antiepileptic Drugs for the Treatment of Epilepsy in Children and Adults
|
|
- Roland Greene
- 5 years ago
- Views:
Transcription
1 The Selection of Antiepileptic Drugs for the Treatment of Epilepsy in Children and Adults Jorge J. Asconape, MD KEYWORDS Epilepsy Seizures Antiepileptic drugs Epilepsy is one of the most common chronic neurologic conditions, affecting as many as 45 million people worldwide. The prevalence of epilepsy in the United States has been estimated at 6 to 8 per 1000 population, with an incidence of 26 to 40 per 100,000 person-years. 1 The incidence of epilepsy has a bimodal distribution, with the highest risk observed in infancy and old age. About two-thirds of the epilepsies are localization-related or partial, and a third generalized. Of the localization-related epilepsies, about two-thirds remain of unknown etiology despite an adequate workup. Approximately 60% to 70% of patients with epilepsy have an adequate response to antiepileptic drug therapy. Most patients with new-onset epilepsy that achieve complete seizure control do so with the first or second medication that they are tried on, regardless of the drug used. 2 Failure to respond to the first 2 antiepileptic drugs (AED), at adequate doses in sequential monotherapy, anticipates refractoriness to medication, and referral to an epilepsy center should not be delayed much further. The management of epilepsy is complex, including AED, hormonal therapies, diet, immunotherapy, surgery (resective or functional), neurostimulation, and behavioral modification techniques. Pharmacologic therapy is by far the most common approach, with the other modalities typically limited to patients with pharmacoresistant epilepsies. In the past 2 decades, 12 new primary AED have been approved by the Food and Drug Administration (FDA) for the treatment of epilepsy (Table 1), making the drug selection process more complex. Some of the challenges in AED selection have been addressed in several treatment guidelines from professional societies, derived from evidence-based medicine analysis, expert opinion surveys, and numerous review articles. 3 9 These guidelines provide a comprehensive review of the available Department of Neurology, Maguire Center, Stritch School of Medicine, Loyola University Chicago, Suite 2700, 2160 South, First Avenue, Maywood, IL 60153, USA address: jasconape@lumc.edu Neurol Clin 28 (2010) doi: /j.ncl neurologic.theclinics.com /10/$ see front matter ª 2010 Elsevier Inc. All rights reserved.
2 844 Asconape Table 1 New antiepileptic drugs Drug Brand Name Year Introduced in USA Felbamate a Felbatol 1993 Gabapentin Neurontin 1994 Lamotrigine Lamictal 1994 Lacosamide Vimpat 2009 Levetiracetam Keppra 1999 Oxcarbazepine Trileptal 2000 Pregabalin Lyrica 2005 Rufinamide Banzel 2008 Tiagabine Gabitril 1997 Topiramate Topamax 1996 Vigabatrin a Sabril 2009 Zonisamide Zonegran 2000 a Restricted used due to serious safety issues. Careful risk-benefit analysis required. literature, and are a great source of information for the clinician when tailoring therapy for an individual patient. BASIC PRINCIPLES OF DRUG SELECTION AED are primarily selected based on the seizure type to be treated. AED can be divided into 2 groups: broad-spectrum and narrow-spectrum drugs (Table 2). Narrow-spectrum drugs are typically effective in partial seizures with or without secondary generalization, somewhat effective in primarily generalized tonic-clonic seizures, and ineffective or prone to worsen absence or myoclonic seizures. Broadspectrum drugs show good efficacy in partial and generalized seizure types, being very useful in situations where the seizure type or the epilepsy syndrome has not Table 2 Spectrum of action of the commonly used antiepileptic drugs Narrow-Spectrum Drugs Partial or Secondarily Generalized Tonic-Clonic Seizures Carbamazepine Gabapentin Lacosamide Oxcarbazepine Phenobarbital Phenytoin Pregabalin Primidone Tiagabine Broad-Spectrum Drugs Partial and Generalized Seizures Lamotrigine Levetiracetam Rufinamide a Topiramate Valproate Zonisamide b a Not approved by FDA for the treatment of partial seizures. No randomized, controlled studies in idiopathic generalized epilepsies. b Class IV evidence. No randomized, controlled studies in idiopathic generalized epilepsies.
3 Selection of Antiepileptic Drugs 845 been well established. Pediatricians and primary care physicians ought to consider using broad-spectrum drugs rather than drugs such as phenobarbital and phenytoin, especially in children and adolescents, given the high incidence of generalized epilepsy syndromes in these age groups. Epilepsies starting in old age, on the other hand, are practically always localization-related (partial or focal). In the selection process of an AED several factors are considered, including its relative efficacy, tolerability, serious toxicity, ease of use (determined by the pharmacokinetic profile and the drug-drug interaction potential), the presence of comorbid conditions, and cost. Age and gender are also important considerations. Relative Efficacy A large body of literature including head-to-head and pivotal clinical trials suggests that AED have a fairly similar relative efficacy against partial seizures. 3 5,10 With the exception of gabapentin and tiagabine, which appear to be less potent, the rest of the drugs including the classic ones are more or less equally effective. In a given patient, however, important differences can be noted among the different AED, making the finding of the most effective drug essentially a trial and error process. Therefore, in patients with partial seizures, relative efficacy is not a useful factor in selecting a particular drug. This is not the case, however, in patients with idiopathic generalized epilepsy, where some important differences in the relative efficacy of the AED have been noted. In a recent large, pragmatic, randomized study of patients with new-onset generalized seizures, valproate was found to be more successful in retaining patients than lamotrigine and topiramate. 11 Patient retention is mostly determined by 2 factors, tolerability and efficacy. Patients on lamotrigine had almost twice the failure rate of those on valproate, mostly due to lack of efficacy, whereas patients on topiramate had a significantly higher failure rate mostly because of side effects. Unfortunately, this study did not include levetiracetam because the drug was not available at the time. Tolerability Tolerability of a drug is one of the most important factors in selecting an AED. Cognitive, behavioral, or sedative side effects frequently complicate the use of these drugs and can have a significant detrimental effect on the quality of life of the patient. These side effects tend to be slightly more common with the classic AED. The relative cognitive effects of the AED are summarized in Table 3. Behavioral reactions are most commonly observed with levetiracetam, phenobarbital, and primidone. AED with the most favorable tolerability profile include lamotrigine and oxcarbazepine. The most common side effects of the AED are shown in Table 4. Table 3 Relative cognitive effects of the antiepileptic drugs None or Minimal Some Significant Gabapentin Lacosamide Lamotrigine Levetiracetam Oxcarbazepine Pregabalin Vigabatrin Carbamazepine Phenytoin Valproate Zonisamide Phenobarbital Primidone Topiramate
4 846 Asconape Table 4 Side effects of the commonly used antiepileptic drugs Drug Common Side Effects Serious Side Effects Carbamazepine Dizziness, diplopia, blurred vision, ataxia, sedation, nausea, neutropenia, rash, a hyponatremia Agranulocytosis, aplastic anemia, hepatic failure, Stevens-Johnson syndrome Lacosamide Lamotrigine Levetiracetam Oxcarbazepine Phenytoin Pregabalin Rufinamide Topiramate Valproate Zonisamide Dizziness, diplopia, blurred vision, headache, nausea Dizziness, diplopia, blurred vision, insomnia, headache, rash Fatigue, dizziness, somnolence, irritability, mood swings Dizziness, diplopia, blurred vision, headache, nausea, hyponatremia Fatigue, dizziness, ataxia, nausea, confusion, gingival hyperplasia, hirsutism, osteopenia, rash Fatigue, dizziness, ataxia, diplopia, weight gain, edema Somnolence, headache, dizziness, diplopia, fatigue, nausea Drowsiness, ataxia, word-finding difficulty, difficulty concentrating, anorexia, weight loss, paresthesias, metabolic acidosis, oligohydrosis, nephrolithiasis Drowsiness, ataxia, tremor, weight gain, hair loss, thrombocytopenia, hyperammonemia Drowsiness, ataxia, difficulty concentrating, anorexia, weight loss, nausea, nephrolithiasis, oligohydrosis PR interval prolongation, atrial fibrillation, atrial flutter, multiorgan hypersensitivity Stevens-Johnson syndrome, toxic epidermal necrolysis, multiorgan failure, hepatic failure Psychosis Stevens-Johnson syndrome, toxic epidermal necrolysis Stevens-Johnson syndrome, toxic epidermal necrolysis, blood dyscrasia, pseudolymphoma, lupus-like syndrome None reported Shortened QT interval (no known clinical risk), multiorgan hypersensitivity Acute close angle glaucoma, heat stroke Hepatic failure, pancreatitis, aplastic anemia, blood dyscrasias, lupus-like syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis Aplastic anemia, rash, Stevens- Johnson syndrome, toxic epidermal necrolysis, heat stroke a HLA-B*1502 testing recommended in patients of Asian descent (haplotype associated with higher risk of Stevens-Johnson syndrome). Serious Toxicity Serious idiosyncratic reactions have been observed with practically every AED, but fortunately are rare, with some notable exceptions. Felbamate use has been associated with a high incidence of idiosyncratic reactions including aplastic anemia and liver failure. The risk of aplastic anemia is higher in females, adults, and those with a history of cytopenia or a prior allergic reaction to AED. Vigabatrin, recently approved in the United States for adjuvant therapy for partial seizures and infantile spasms, is
5 Selection of Antiepileptic Drugs 847 associated with an irreversible retinopathy. After an average exposure of 6 to 9 months, a gradual, progressive constriction of the visual fields has been detected, with a prevalence of 25% to 50% in adults and 15% to 30% in infants. These 2 AED have a very limited role in the therapy for epilepsy, and should only be used after a very careful risk-benefit analysis. The risk of valproate-associated hepatotoxicity is about 1 in 20,000 to 100,000, but has been found to be considerably higher in children younger than 2 years, in the presence of polytherapy or developmental problems. When all 3 risk factors are present, the risk of liver failure approaches 1 in Valproate should be used with caution in this age group. The risk of Stevens-Johnson syndrome or toxic epidermal necrolysis with the use of carbamazepine is significantly increased in patients with the HLA allele HLA-B*1502, found almost exclusively in people of Asian descent. 13 It has been recommended that patients of Asian ancestry be screened for this allele before initiating treatment with carbamazepine. Rash is the most common, potentially serious idiosyncratic reaction that the clinician faces in daily practice. Rash has been reported with almost every AED, but is more commonly observed with drugs such as carbamazepine, oxcarbazepine, lamotrigine, phenytoin, and zonisamide. When facing a patient with prior history of rash, the following AED are considered safer: levetiracetam, gabapentin, pregabalin, topiramate, and valproate. Ease of Use One of the clearest advantages of the newer AED over the classic ones has been their more favorable pharmacokinetic and drug-drug interaction profiles. The older AED such as phenytoin, carbamazepine, phenobarbital, and primidone are potent inducers of the cytochrome P450 enzymatic system, resulting in significant drug-drug interactions with a long list of medications commonly used in clinical practice (Fig. 1; Table 5). 14 This enzyme-inducing effect seems to be in part responsible for the high incidence of osteopenia observed in patients taking these AED, presumably by accelerating the metabolism of vitamin D. The newer AED have much more favorable pharmacokinetics, with generally good oral bioavailability, low protein binding, linear kinetics, lack of active metabolites and low potential for drug-drug interactions (Table 6). Box 1 lists some of the shortcomings of the older AED. Comorbidities The presence of hepatic or renal insufficiency can impair the elimination of the AED, leading to accumulation of the parent drug and clinical toxicity. Avoiding drugs that Fig. 1. Effects of antiepileptic drugs on the cytochrome P450.
6 848 Asconape Table 5 Increased clearance of commonly used drugs in the presence of enzyme-inducing antiepileptic drugs (carbamazepine, phenobarbital, phenytoin, and primidone) Drug Type Antiepileptic Psychiatric Cardiac Antineoplastic Anti-infective Immunosuppressants Other Increased Clearance (Higher Doses Needed) Lacosamide, lamotrigine, oxcarbazepine, rufinamide, tiagabine, topiramate, valproate, zonisamide, diazepam Amitriptyline, nortriptyline, imipramine, desipramine, clomipramine, citalopram, paroxetine, buproprion, haloperidol, chlorpromazine, clozapine, olanzapine, risperidone, quetiapine Mexiletine, quinidine, amiodarone, propranolol, metoprolol, nifedipine, felodipine, nimodipine, digoxin, lovastatin, simvastatin, dicumarol, warfarin Cyclophosphamide, busulfan, etoposide, methotrexate, teniposide, some vinca alkaloids Praziquantel, albendazole, doxycycline, nevirapine, efavirenz, delavirdine, indinavir, ritonavir, saquinavir Cyclosporine, tacrolimus Oral contraceptive pills, prednisone, theophylline, methadone Modified from Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interaction between antiepileptic drugs and other drugs. Lancet Neurol 2003;2:473 81; with permission. are eliminated predominantly by the affected organ has obvious benefits. The classic AED are mostly dependent on hepatic metabolism for their elimination and may be problematic in patients with liver disease. The relative contribution of the liver and kidney in the elimination of the newer AED is summarized in Fig. 2. Comorbid conditions in patients with epilepsy often are determinant in the selection of an AED. Certain comorbid conditions may benefit or worsen, directly or indirectly, from a particular AED. In patients with obesity, drugs such as topiramate and zonisamide are often used because of their tendency to promote weight loss. Other AED can promote weight gain. Valproate and pregabalin are associated with significant weight gain, whereas gabapentin and carbamazepine have a more modest effect. Table 6 Relative drug-drug interaction potential of the antiepileptic drugs None Low a High Ethosuximide Gabapentin Levetiracetam Pregabalin Vigabatrin Lacosamide Lamotrigine Oxcarbazepine b Rufinamide Topiramate b Tiagabine Zonisamide Carbamazepine Felbamate Phenytoin Phenobarbital Primidone Valproate a These drugs generally do not affect other drugs, but are usually targets of the High potential group. b These drugs inhibit the CYP 2C19 and may increase serum levels of phenytoin. They also have a mild, dose-dependent inducing effect on the metabolism of oral contraceptives.
7 Selection of Antiepileptic Drugs 849 Box 1 Pharmacokinetic issues with the older antiepileptic drugs High protein bound fraction (phenytoin, valproate) Nonlinear kinetics Saturable metabolism (phenytoin) Autoinduction (carbamazepine) Active metabolites (carbamazepine, primidone) P450 enzyme induction (phenytoin, carbamazepine, primidone, phenobarbital) P450 enzyme inhibition (valproate) Numerous drug interactions (phenytoin, carbamazepine, valproate, phenobarbital, primidone) The incidence of migraine in patients with epilepsy is higher than in the general population. Certain AED have shown good efficacy for the prophylaxis of migraine for several decades (Box 2), and often a single drug can treat both conditions effectively. Psychiatric comorbidities are extremely common in patients with epilepsy. Depression, anxiety disorders, panic disorder, psychosis, attention deficit disorders, and autistic disorders are overrepresented in patients with epilepsy. AED can have significant, either positive or negative, effects on mood. AED associated with a higher risk of depression include levetiracetam, phenobarbital, primidone, topiramate, vigabatrin, and zonisamide. AED with a positive psychotropic effect include carbamazepine, lamotrigine, oxcarbazepine, and valproate. Almost every AED can cause or worsen attention deficit disorders, but the most common offenders include phenobarbital, primidone, benzodiazepines, and vigabatrin. SELECTION OF AED IN WOMEN In young females, valproate has been associated with a higher incidence of polycystic ovarian syndrome, presenting with dysmenorrhea, anovulatory cycles, hyperandrogenism, and weight gain. The mechanism is not well understood, but the drug appears to play an important role. Enzyme-inducing AED such as phenobarbital, phenytoin, and carbamazepine increase the clearance of oral contraceptives, and may result in a pill failure unless Fig. 2. Routes of elimination of the newer antiepileptic drugs.
8 850 Asconape Box 2 AED use in migraine prophylaxis FDA-approved indication Valproate a Topiramate a AED without FDA-approved indication Gabapentin a Lamotrigine Levetiracetam Pregabalin Zonisamide a Class I level of evidence. higher doses are used (at least 50 mg of ethinyl estradiol). Oxcarbazepine and topiramate may also decrease the effectiveness of oral contraceptives, but they have a weaker, dose-dependent effect. Oral contraceptives increase the clearance of lamotrigine and adjustments to the dose of lamotrigine can be necessary. An increased rate of congenital malformations has been observed in the offspring of women taking AED during pregnancy. These drugs are relatively weak teratogens, and for the majority of women with epilepsy the benefits of AED therapy offset the potential risks. Information on the relative teratogenic risk of each AED is limited, and no drug can be considered safe. Valproate and phenobarbital, however, have consistently shown significantly higher malformation rates than the other AED and should be avoided whenever possible. Children exposed to valproate in utero have shown lower IQ scores and higher rates of developmental delay. Phenobarbital probably has a similar effect. The risk appears maximal with exposure during the third trimester of pregnancy. EPILEPSY IN THE ELDERLY The incidence of epilepsy increases dramatically after the age of 60 years. When the epilepsy starts late in life, it is almost always localization-related, seizures can be subtle or atypical, response to therapy is usually good, and the condition does not remit, so life-long therapy is usually required. Elderly patients with epilepsy typically have several comorbid conditions and frequently take several other drugs. AED with no drug interaction potential should be selected whenever possible. The elderly are more susceptible to some of the common side effects of AED such as dizziness or ataxia. Drugs such as carbamazepine, phenytoin, or oxcarbazepine tend to be poorly tolerated, and may increase the risk of falls in this population. Cognitive issues are also a concern, making phenytoin, phenobarbital, topiramate, or zonisamide less desirable choices. AED with a favorable profile for an elderly patient include lamotrigine, pregabalin, and levetiracetam. A slow titration and conservative maintenance doses are especially important in the elderly. DRUG OF CHOICE FOR NEWLY DIAGNOSED EPILEPSY The tradition of recognizing a first-choice drug for a certain seizure type or epilepsy syndrome is no longer practical. With so many AED available, depending on several
9 Selection of Antiepileptic Drugs 851 factors such age, gender, comorbidities, and cost, different patients with a similar type of epilepsy may be prescribed different AED. The following are some general practical recommendations for a hypothetical patient with no confounding factors (ie, a young male with epilepsy, otherwise healthy). New-Onset Partial Epilepsy (Partial and Secondary Generalized Tonic-Clonic Seizures) First tier: these drugs have the most favorable tolerability and pharmacokinetic profiles: Lamotrigine or oxcarbazepine are good initial choices for adults. In children, due to the increased risk of serious rash with lamotrigine, oxcarbazepine would be first choice. If cost is an overriding issue, carbamazepine is a reasonable first choice. Second tier: these drugs have some tolerability or pharmacokinetic issues: Levetiracetam (behavioral side effects), topiramate (cognitive side effects), pregabalin (weight gain), valproate (weight gain, women s issues, drug interactions), zonisamide (cognitive side effects). Obsolete: due to most unfavorable pharmacokinetic and tolerability profiles: Phenytoin, phenobarbital, primidone. New-Onset Generalized Epilepsy Childhood absence First tier: Ethosuximide, valproate, lamotrigine Second tier: Levetiracetam, zonisamide, topiramate, clonazepam Idiopathic generalized epilepsy of adolescence (includes juvenile myoclonic, juvenile absence epilepsy, idiopathic generalized epilepsy with generalized tonic-clonic seizures on awakening, photosensitive epilepsy): In this group of very common epilepsies, valproate remains the most effective agent. However, in women of child-bearing age, due to its adverse side effect profile, it is only recommended when other drugs have failed. In nonobese men it remains as a reasonable first choice. First tier: Valproate, lamotrigine, levetiracetam, topiramate Second tier: Zonisamide, benzodiazepines Lennox-Gastaut syndrome: this syndrome is often refractory to pharmacologic therapy, with multiple drug combinations or nonpharmacologic therapies usually needed. Broad-spectrum drugs are preferred initially. First tier: Lamotrigine, levetiracetam, rufinamide, topiramate, valproate, zonisamide Second tier: Felbamate, benzodiazepines SUMMARY Clinicians practice in an era of abundance of AED, making the selection of a drug a more complex process, but at the same time providing an opportunity to better meet the needs of more patients. The newer AED have shown no better efficacy than the classic drugs, but they are easier to use, with much better pharmacokinetic profiles and fewer drug interactions. AED have also expanded the availability of broadspectrum drugs, a major benefit for patients with generalized epilepsies. The long list
10 852 Asconape of available AED has also benefited patients with epilepsy and comorbidities, often allowing for the use of drugs with positive effects or at least no negative effects on those conditions. REFERENCES 1. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: Epilepsia 1993;34: Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342: Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidenced-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006;47(7): French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of refractory epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62: French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of new onset epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62: Karceski S, Morrell MJ, Carpenter D. Treatment of epilepsy in adults: expert opinion, Epilepsy Behav 2005;7:S Wheless JW, Clarke DF, Arzimanoglou A, et al. Treatment of pediatric epilepsy: European expert opinion, Epileptic Disord 2007;9(4): National Institute for Clinical Excellence (NICE). Newer drugs for epilepsy (technology appraisal 76). London: National Institute for Clinical Excellence; French JA, Pedley TA. Initial management of epilepsy. N Engl J Med 2008;359: Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled study. Lancet 2007;369: Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of Valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled study. Lancet 2007;369: Bryant AE, Dreifuss FE. Valproic acid fatalities III. US experience since Neurology 1996;46: Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens- Johnson syndrome. Nature 2004;428: Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interaction between antiepileptic drugs and other drugs. Lancet Neurol 2003;2:
Disclosure. Learning Objectives
Linda D. Leary, M.D. Associate Clinical Professor of Pediatrics & Neurology South Texas Comprehensive Epilepsy Center UT Health Science Center San Antonio Disclosure Linda D. Leary, M.D. discloses the
More informationNew antiepileptic drugs
Chapter 29 New antiepileptic drugs J.W. SANDER UCL Institute of Neurology, University College London, National Hospital for Neurology and Neurosurgery, Queen Square, London, and Epilepsy Society, Chalfont
More informationAED Treatment Approaches. David Spencer, MD Director, OHSU Epilepsy Center Professor, Department of Neurology
AED Treatment Approaches David Spencer, MD Director, OHSU Epilepsy Center Professor, Department of Neurology Audience Response Keypads Please utilize the keypad at your table to answer questions throughout
More informationEpilepsy 101. Overview of Treatment Kathryn A. O Hara RN. American Epilepsy Society
Epilepsy 101 Overview of Treatment Kathryn A. O Hara RN American Epilepsy Society Objectives Describe the main treatment options for epilepsy Identify factors essential in the selection of appropriate
More informationSeizure medications An overview
Seizure medications An overview Andrew Zillgitt, DO Staff Neurologist Comprehensive Epilepsy Center Department of Neurology Henry Ford Hospital None Disclosures Objectives A lot to review!!!!! Look at
More informationAntiepileptics. Medications Comment Quantity Limit Carbamazepine. May be subject Preferred to quantity limit Epitol
Market DC Antiepileptics Override(s) Approval Duration Prior Authorization 1 year Step Therapy Quantity Limit *Indiana Medicaid See State Specific Mandate below *Maryland Medicaid See State Specific Mandate
More informationPrescribing and Monitoring Anti-Epileptic Drugs
Prescribing and Monitoring Anti-Epileptic Drugs Mark Granner, MD Clinical Professor and Vice Chair for Clinical Programs Director, Iowa Comprehensive Epilepsy Program Department of Neurology University
More informationEpilepsy 7/28/09! Definitions. Classification of epilepsy. Epidemiology of Seizures and Epilepsy. International classification of epilepsies
Definitions Epilepsy Dr.Yotin Chinvarun M.D., Ph.D. Seizure: the clinical manifestation of an abnormal and excessive excitation of a population of cortical neurons Epilepsy: a tendency toward recurrent
More informationAnticonvulsants Antiseizure
Anticonvulsants Antiseizure Seizure disorders Head trauma Stroke Drugs (overdose, withdrawal) Brain tumor Encephalitis/ Meningitis High fever Hypoglycemia Hypocalcemia Hypoxia genetic factors Epileptic
More informationTreatment of epilepsy in adults
Treatment of epilepsy in adults Review 33 Treatment of epilepsy in adults S B Gunatilake 1, A Arasalingam 2 Sri Lanka Journal of Neurology, 2012, 1, 33-38 Case vignettes 1. A 60-year old patient with long
More informationReview of Anticonvulsant Medications: Traditional and Alternative Uses. Andrea Michel, PharmD, CACP
Review of Anticonvulsant Medications: Traditional and Alternative Uses Andrea Michel, PharmD, CACP Objectives Review epidemiology of epilepsy Classify types of seizures Discuss non-pharmacologic and pharmacologic
More informationZONISAMIDE THERAPEUTICS. Brands * Zonegran. Generic? Not in US. If It Doesn t Work * Class Antiepileptic drug (AED), structurally a sulfonamide
Z:/3-PAGINATION/SBT/2-PROOFS/NWMS/9780521136723C111//9780521136723C111.3D 376 [376 380] ZONISAMIDE Brands Zonegran Generic? Not in US THERAPEUTICS Class Antiepileptic drug (AED), structurally a sulfonamide
More informationMedications for Epilepsy What I Need to Know
Medications for Epilepsy What I Need to Know Safiya Ladak, BSc.Phm. Toronto Western Hospital, UHN Clinical Pharmacist, Neurology and Neurosurgery June 4, 2016 Learning Objectives Treatment options for
More informationUpdated advice for nurses who care for patients with epilepsy
NICE BULLETIN Updated advice for nurses who care for patients with epilepsy NICE provided the content for this booklet which is independent of any company or product advertised NICE BULLETIN Updated advice
More informationWhen choosing an antiepileptic ... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs. Based on a presentation by Barry E.
... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs Based on a presentation by Barry E. Gidal, PharmD Presentation Summary A physician s choice of an antiepileptic drug (AED) usually depends
More informationDisclosures. AED Options. Epilepsy Pharmacotherapy: Treatment Considerations with Older AEDs
Epilepsy Pharmacotherapy: Treatment Considerations with Older AEDs BARRY E. GIDAL, PHARMD PROFESSOR SCHOOL OF PHARMACY & DEPT. OF NEUROLOGY Disclosures Speaking honoraria: UCB, Eisai, Sunovion Consultant:
More information2018 American Academy of Neurology
Practice Guideline Update Efficacy and Tolerability of the New Antiepileptic Drugs I: Treatment of New-Onset Epilepsy Report by: Guideline Development, Dissemination, and Implementation Subcommittee of
More informationEpilepsy Medications: The Basics
Epilepsy Medications: The Basics B R I A N A P P A V U, M D C L I N I C A L A S S I S T A N T P R O F E S S O R, D E P A R T M E N T O F C H I L D H E A L T H A N D N E U R O L O G Y, U N I V E R S I T
More informationOpinion 24 July 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 24 July 2013 FYCOMPA 2 mg, film-coated tablet B/7 (CIP: 34009 267 760 0 8) B/28 (CIP: 34009 268 447 4 5) FYCOMPA 4
More informationErnie Somerville Prince of Wales Hospital EPILEPSY
Ernie Somerville Prince of Wales Hospital EPILEPSY Overview Classification New and old anti-epileptic drugs (AEDs) Neuropsychiatric side-effects Limbic encephalitis Non-drug therapies Therapeutic wishlist
More information2018 American Academy of Neurology
Practice Guideline Update Efficacy and Tolerability of the New Antiepileptic Drugs II: Treatment-Resistant Epilepsy Report by: Guideline Development, Dissemination, and Implementation Subcommittee of the
More informationEpilepsy is a very individualized
... PRESENTATION... Treatment of Epilepsy in 3 Specialized Populations Based on a presentation by Ilo E. Leppik, MD Presentation Summary When discussing the treatment of epilepsy, targeted populations
More informationPharmacy Medical Necessity Guidelines: Anticonvulsants/Mood Stabilizers
Pharmacy Medical Necessity Guidelines: Anticonvulsants/Mood Stabilizers Effective: December 18, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review
More informationEpilepsy and EEG in Clinical Practice
Mayo School of Professional Development Epilepsy and EEG in Clinical Practice November 10-12, 2016 Hard Rock Hotel at Universal Orlando Orlando, FL Course Directors Jeffrey Britton, MD and William Tatum,
More informationEpilepsy is one of the more common
PART ONE An Overview of Medications Used in Epilepsy Parents, families and caregivers, as well as persons with epilepsy, frequently have questions about medications and often turn to the Internet for information
More informationEPILEPSY: SPECTRUM OF CHANGE WITH AGE. Gail D. Anderson, Ph.D.
EPILEPSY: SPECTRUM OF CHANGE WITH AGE Gail D. Anderson, Ph.D. Incidence: 0.5% - 1.0% of U.S. population Peak incidence of onset: first 2 years of life, ages 5-7 years, early puberty and elderly. 125,000
More information11/7/2018 EPILEPSY UPDATE. Dr.Ram Sankaraneni. Disclosures. Speaker bureau LivaNova
EPILEPSY UPDATE Dr.Ram Sankaraneni Disclosures Speaker bureau LivaNova 1 Outline New onset Seizure Investigations in patients with epilepsy Medical management of epilepsy Non Pharmacological options in
More informationTherapeutic strategies in the choice of antiepileptic drugs
Acta neurol. belg., 2002, 102, 6-10 Original articles Therapeutic strategies in the choice of antiepileptic drugs V. DE BORCHGRAVE, V. DELVAUX, M. DE TOURCHANINOFF, J.M. DUBRU, S. GHARIANI, Th. GRISAR,
More information7/31/09. New AEDs. AEDs. Dr. Yotin Chinvarun M.D. Ph.D. Comprehensive Epilepsy and Sleep disorder Program PMK hospital. 1 st genera*on AEDs
Dr. Yotin Chinvarun M.D. Ph.D. Comprehensive Epilepsy and Sleep disorder Program PMK hospital New AEDs AEDs NEW OLD Pregabalin Pregabalin 1 st genera*on AEDs Phenytoin Carbamazepine Valproate Phenobarbital
More informationEpilepsy characterized by recurrent and unprovoked
Literature Review New Antiepileptic Agents Linda P. Nelson, DMD, MScD Ilse Savelli-Castillo, DDS Dr. Nelson is associate in dentistry, Department of Pediatric Dentistry, Children s Hospital, and is assistant
More informationSEIZURES PHARMACOLOGY. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
SEIZURES PHARMACOLOGY University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 Understand the pharmacodynamics involved in the medications used to treat seizures
More informationSODIUM CHANNEL BLOCKERS IN THE 21 ST CENTURY. Professor Martin J Brodie University of Glasgow Glasgow, Scotland
IN THE 21 ST CENTURY Professor Martin J Brodie University of Glasgow Glasgow, Scotland Eisai SODIUM CHANNEL BLOCKERS Declaration of interests UCB Pharma GlaxoSmithKline Lundbeck Takeda Advisory board,
More informationTRANSPARENCY COMMITTEE OPINION. 19 July 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 July 2006 Keppra 250 mg, film-coated tablets Box of 60 tablets (CIP code: 356 013-6) Keppra 500 mg, film-coated
More informationDone by: Rola Awad Presented to : Dr. Diana Malaeb Date: 28/2/2013
Done by: Rola Awad Presented to : Dr. Diana Malaeb Date: 28/2/2013 1 Abbreviations AED: antiepileptic drug EEG: electroencephalography SJS: Stevens Johnson syndrome VA: Valproic acid GABA : Gamma amino
More informationChildren Are Not Just Small Adults Choosing AEDs in Children
Children Are Not Just Small Adults Choosing AEDs in Children Natrujee Wiwattanadittakun, MD Neurology division, Department of Pediatrics, Chiang Mai University Hospital, Chiang Mai University 20 th July,
More informationModified release drug delivery system for antiepileptic drug (Formulation development and evaluation).
TITLE OF THE THESIS / RESEARCH: Modified release drug delivery system for antiepileptic drug (Formulation development and evaluation). INTRODUCTION: Epilepsy is a common chronic neurological disorder characterized
More informationOptimizing Antiepileptic Drug Therapy in Refractory Epilepsy
15 Optimizing Antiepileptic Drug Therapy in Refractory Epilepsy Nicholas P. Poolos Department of Neurology and UW Regional Epilepsy Center, University of Washington, Seattle, WA, USA Introduction: When
More informationWHY CHILDREN ARE DIFFERENT FROM ADULTS
XXASIM May p159-165 5/14/01 9:23 AM Page 159 NEW PHARMACOLOGICAL TREATMENTS FOR PEDIATRIC EPILEPSY Blaise F.D. Bourgeois, MD KEY POINTS Antiepileptic drugs (AEDs) are tailored to pediatric epilepsy seizure
More informationUnderstanding and Managing Epilepsy
Page 1 Understanding and Managing Epilepsy Jacquelyn L. Bainbridge, Pharm.D., FCCP Associate Professor University of Colorado Denver School of Pharmacy & Department of Neurology Supported by an educational
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Absence seizures, 6 in childhood, 95 Adults, seizures and status epilepticus in, management of, 34 35 with first-time seizures. See Seizure(s),
More informationManagement of Epilepsy in Primary Care and the Community. Carrie Burke, Epilepsy Specialist Nurse
Management of Epilepsy in Primary Care and the Community Carrie Burke, Epilepsy Specialist Nurse Epilepsy & Seizures Epilepsy is a common neurological disorder characterised by recurring seizures (NICE,
More informationGeneric Name (Brand Name) Available Strengths Formulary Limits. Primidone (Mysoline) 50mg, 250mg -- $
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Epilepsy P&T DATE: 2/15/2017 THERAPEUTIC CLASS: Neurologic Disorders REVIEW HISTORY: 2/16 LOB AFFECTED: Medi-Cal (MONTH/YEAR)
More informationEpilepsy T.I.A. Cataplexy. Nonepileptic seizure. syncope. Dystonia. Epilepsy & other attack disorders Overview
: Clinical presentation and management Markus Reuber Professor of Clinical Neurology Academic Neurology Unit University of Sheffield, Royal Hallamshire Hospital. Is it epilepsy? Overview Common attack
More informationEfficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy
Special Article Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee
More informationLAMICTAL GlaxoSmithKline
LAMICTAL GlaxoSmithKline Lamotrigine QUALITATIVE AND QUANTITATIVE COMPOSITION Tablets: LAMICTAL, 25, 50, 100 and 200 mg. Dispersible/Chewable Tablets: LAMICTAL, 2, 5, 25, 50, 100 and 200 mg. PHARMACEUTICAL
More information3/27/2013. T/F Seizures are waves of abnormal electrical activity in the brain
To understand the different types of seizure disorders To identify the basic pharmacological principles in management of seizure disorders To identify the common non-pharmacologic therapies for seizures
More informationNewer Anticonvulsants: Targets and Toxicity. Laura Tormoehlen, MD Neurology and EM-Toxicology
Newer Anticonvulsants: Targets and Toxicity Laura Tormoehlen, MD Neurology and EM-Toxicology Disclosures No financial disclosures DEFINITIONS Objectives/Outline Mechanism of Action Specific Indications
More informationEpilepsy management What, when and how?
Epilepsy management What, when and how? J Helen Cross UCL-Institute of Child Health, Great Ormond Street Hospital for Children, London, & National Centre for Young People with Epilepsy, Lingfield, UK What
More informationAntiepilepsy Drugs: Pharmacodynamics and Principles of Drug Selection
Epilepsy Board Review Manual Statement of Editorial Purpose The Epilepsy Board Review Manual is a study guide for trainees and practicing physicians preparing for board examinations in epilepsy. Each manual
More informationANTIEPILEPTIC DRUGS. Hiwa K. Saaed, PhD. Department of Pharmacology & Toxicology College of Pharmacy University of Sulaimani
ANTIEPILEPTIC DRUGS Hiwa K. Saaed, PhD Department of Pharmacology & Toxicology College of Pharmacy University of Sulaimani 2017-18 Antiepileptic drugs (AEDs) Definitions and Terminology Historical overview
More informationNew Patient Questionnaire - Epilepsy
New Patient Questionnaire - Epilepsy Person completing this form: (if other than the patient) GENERAL SEIZURE HISTORY Relationship: When do you think your child had their first seizure? When was the last
More informationAnti-epileptic drugs: a guide for the non-neurologist
OCCASIONAL PAPERS Clinical Medicine 2010, Vol 10, No 1: 54 8 Anti-epileptic drugs: a guide for the non-neurologist Joseph Anderson and Carl-Christian Moor ABSTRACT Epilepsy is the most common serious chronic
More informationMay 2005 Seizure Disorders: Review of Therapeutic Options H01
W-F Professional Associates, Inc. 400 Lake Cook Rd., Suite 207 Deerfield, IL 60015 847-945-8050 May 2005 Seizure Disorders: Review of Therapeutic Options 707-000-05-005-H01 IT S ALWAYS A GOOD IDEA TO GET
More informationNew AEDs in Uncontrolled seizures
New AEDs in Uncontrolled seizures Uncontrolled seizures/epilepsy Intractable epilepsy, Refractory epilepsy, Pharmacoresistant epilepsy Dr. Suthida Yenjun Traditionally, referred to therapeutic failure
More informationThe epilepsies: pharmacological treatment by epilepsy syndrome
The epilepsies: pharmacological treatment by epilepsy syndrome This table provides a summary reference guide to pharmacological treatment. Anti-epileptic drug (AED) options by epilepsy syndrome Childhood
More informationOptimizing Management of Seizure Disorders
708 Medicine Update 121 Optimizing Management of Seizure Disorders V NAGARAJAN INTRODUCTION Seizure disorders are met with by every consultant in practice almost everyday. In the management of seizure
More informationPharmacological Treatment of Non-Lesional Epilepsy December 8, 2013
Pharmacological Treatment of Non-Lesional Epilepsy December 8, 2013 Michael Privitera, MD Professor of Neurology University of Cincinnati, Neuroscience Institute American Epilepsy Society Annual Meeting
More informationEpilepsy: pharmacological treatment by seizure type. Clinical audit tool. Implementing NICE guidance
Epilepsy: pharmacological treatment by seizure type Clinical audit tool Implementing NICE guidance 2012 NICE clinical guideline 137 Clinical audit tool: Epilepsy (2012) Page 1 of 25 This clinical audit
More informationAN UPDATE ON ANTIEPILEPTIC AGENTS: FOCUS ON AN UPDATE ON ANTIEPILEPTIC AGENTS: FOCUS ON SECOND GENERATION TREATMENT OPTIONS
Volume 24, Issue 1 October 2008 AN UPDATE ON ANTIEPILEPTIC AGENTS: FOCUS ON SECOND GENERATION TREATMENT OPTIONS Jason Richey, Pharm.D. Candidate Epilepsy is a neurological disorder characterized by sudden
More informationI. Introduction Epilepsy is the tendency to have recurrent seizures unprovoked by systemic or acute neurologic insults. Antiepileptic drugs (AEDs)
1 2 I. Introduction Epilepsy is the tendency to have recurrent seizures unprovoked by systemic or acute neurologic insults. Antiepileptic drugs (AEDs) are those which decrease the frequency and/or severity
More informationIntroduction. 1 person in 20 will have an epileptic seizure at some time in their life
Introduction 1 person in 20 will have an epileptic seizure at some time in their life Epilepsy is diagnosed on the basis of two or more epileptic seizures. Around 450,000 people in the UK have epilepsy
More informationTypes of epilepsy. 1)Generalized type: seizure activity involve the whole brain, it is divided into:
Types of epilepsy We have different types of epilepsy, so it is not one type of seizures that the patient can suffer from; we can find some patients with generalized or partial seizure. So, there are two
More informationTITLE: Pharmacological Treatments in Patients with Epilepsy: Guidelines
TITLE: Pharmacological Treatments in Patients with Epilepsy: Guidelines DATE: 01 April 2011 RESEARCH QUESTION What are the evidence-based guidelines for pharmacological treatments in patients with epilepsy?
More information8/30/10. How to use Antiepileptic drugs properly. 3nd generation AEDs. Introduction. Introduction. Introduction. AEDs. Dr.Yotin Chinvarun M.D., Ph.D.
Introduction How to use Antiepileptic drugs properly Modern treatment of seizures started in 1850 with the introduction of bromides, based on the theory that epilepsy was caused by an excessive sex drive
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lamotrigin Medochemie 25 mg tablets Lamotrigin Medochemie 50 mg tablets Lamotrigin Medochemie 100 mg tablets Lamotrigin Medochemie 200
More informationAdvances in the diagnosis and management of epilepsy in adults
n DRUG REVIEW Advances in the diagnosis and management of epilepsy in adults Diego Kaski MRCP, PhD and Charles Cockerell MD, FRCP SPL This drug review looks at the key issues in diagnosing epilepsy, initiating
More informationLMMG New Medicine Recommendation
LMMG New Medicine Recommendation Oxcarbazepine (Trileptal ) for the treatment of epilepsy LMMG Recommendation: Amber 0: Oxcarbazepine (Trileptal ) is recommended for use as monotherapy or adjunctive therapy
More informationEpilepsy. Annual Incidence. Adult Epilepsy Update
Adult Epilepsy Update Annual Incidence J. Layne Moore, MD, MPH Associate Professor Department of Neurology and Pharmacy Director, Division of Epilepsy The Ohio State University Used by permission Health
More informationAPPENDIX K Pharmacological Management
1 2 3 4 APPENDIX K Pharmacological Management Table 1 AED options by seizure type Table 1 AED options by seizure type Seizure type First-line AEDs Adjunctive AEDs Generalised tonic clonic Lamotrigine Oxcarbazepine
More informationOn completion of this chapter you should be able to: list the most common types of childhood epilepsies and their symptoms
9 Epilepsy The incidence of epilepsy is highest in the first two decades of life. It falls after that only to rise again in late life. Epilepsy is one of the most common chronic neurological condition
More informationThe Epilepsy Prescriber s Guide to Antiepileptic Drugs
The Epilepsy Prescriber s Guide to Antiepileptic Drugs The Epilepsy Prescriber s Guide to Antiepileptic Drugs Philip N. Patsalos FRCPath, PhD Professor of Clinical Pharmacology and Consultant Clinical
More informationimproving the patient s quality of life.
Epilepsy is the tendency to have recurrent seizures unprovoked by systemic or acute neurologic insults. Antiepileptic drugs (AEDs) are those which decrease the frequency and/or severity of seizures in
More informationThe Diagnostic Detective: Epilepsy
The Diagnostic Detective: Epilepsy Some Facts About Epilepsy and Its Causes Seizures are the most common neurologic disorders affecting children 5% of children have a seizure during childhood There are
More informationARTICLES Monotherapy in adults and elderly persons
ARTICLES Monotherapy in adults and elderly persons Edward Faught, MD Address correspondence and reprint requests to Dr. Edward Faught, Department of Neurology, University of Alabama at Birmingham Epilepsy
More informationTHE TREATMENT GAP AND POSSIBLE THERAPIES OF EPILEPSY IN SUB- SAHARAN AFRICA
THE TREATMENT GAP AND POSSIBLE THERAPIES OF EPILEPSY IN SUB- SAHARAN AFRICA DR A.O. CHARWAY-FELLI, MD, PhD NEUROLOGIST 37 MILITARY HOSPITAL, ACCRA, GHANA SECRETARY-GENERAL AFRICAN ACADEMY OF NEUROLOGY
More informationClinical Policy: Clobazam (Onfi) Reference Number: CP.PMN.54 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Onfi) Reference Number: CP.PMN.54 Effective Date: 11.01.12 Last Review Date: 08.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationClinical Policy: Clobazam (Onfi) Reference Number: CP.PMN.54 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Onfi) Reference Number: CP.PMN.54 Effective Date: 11.01.12 Last Review Date: 11.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationChapter 15. Media Directory. Convulsion. Seizures. Epilepsy. Known Causes of Seizures. Drugs for Seizures
Chapter 15 Drugs for Seizures Slide 43 Slide 45 Media Directory Diazepam Animation Valproic Acid Animation Upper Saddle River, New Jersey 07458 All rights reserved. Seizures Convulsion Abnormal or uncontrolled
More informationlevetiracetam 250,500,750 and 1000mg tablets and levetiracetam oral solution 100mg/1ml (Keppra ) (No. 397/07) UCB Pharma Ltd
Scottish Medicines Consortium Resubmission levetiracetam 250,500,750 and 1000mg tablets and levetiracetam oral solution 100mg/1ml (Keppra ) (No. 397/07) UCB Pharma Ltd 11 January 2008 The Scottish Medicines
More informationLamotrigine 2 mg, 5 mg, 25 mg, 50 mg, 100 mg, 200 mg dispersible/chewable tablets
Arrow - Lamotrigine Lamotrigine 2 mg, 5 mg, 25 mg, 50 mg, 100 mg, 200 mg dispersible/chewable tablets Presentation Arrow - Lamotrigine 2 mg White to off-white, round tablets embossed with 'LI' over '2'
More informationAntiepileptic Drugs for Pediatric Seizures
Antiepileptic Drugs for Pediatric Seizures Ashley Beagle, PharmD PGY2 Pediatric Pharmacy Resident University of Iowa Stead Family Children s Hospital JCPA Monthly Meeting March 20 th, 2018 Header Disclosure
More informationAntiepileptic Drugs for Pediatric Seizures
Header Disclosure Text Antiepileptic Drugs for Pediatric Seizures Ashley Beagle reports that she has no actual or potential conflicts of interest in relation to this presentation Off label use of medications
More informationInitial Treatment of Seizures in Childhood
Initial Treatment of Seizures in Childhood Roderic L. Smith, MD, Ph.D. Pediatric Neurology Clinic of Alaska,PC Incidence of Seizures Overall 5% by age 20 yrs. Lifetime risk= 5-10% CNS Infections= 5% TBI=10%
More informationContemporary Developments in Childhood Epilepsy Management. Olivia O Mahony, Cork University Hospital, Cork, and Mercy University Hospital
Contemporary Developments in Childhood Epilepsy Management Olivia O Mahony, Cork University Hospital, Cork, and Mercy University Hospital Developments in Epilepsy Care Standardised epilepsy care using
More informationUpdate in Clinical Guidelines in Epilepsy
Why We Need Clinical Guidelines? Clinician needs advice! Update in Clinical Guidelines in Epilepsy Charcrin Nabangchang, M.D. Phramongkutklao College of Medicine Tiamkao S, Neurology Asia2013 Why We Need
More informationDOSAGE FORMS AND STRENGTHS Tablets: 25 mg, 100 mg, 150 mg, and 200 mg; scored. (3.1, 16)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LAMOTRIGINE TABLETS safely and effectively. See full prescribing information for LAMOTRIGINE TABLETS.
More informationSee 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: May 2009 LMT:2PI
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LAMICTAL safely and effectively. See full prescribing information for LAMICTAL. LAMICTAL (lamotrigine)
More informationEpilepsy and Epileptic Seizures
Epilepsy and Epileptic Seizures Petr Marusič Dpt. of Neurology Charles University, Second Faculty of Medicine Motol University Hospital Diagnosis Steps Differentiation of nonepileptic events Seizure classification
More informationThe epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care Issued: January 2012 last modified: January 2015 guidance.nice.org.uk/cg137 NICE has
More informationCLINICIAN INTERVIEW AS i M: When you examine a clinical trial in new- onset epilepsy, how relevant are the results to your daily clinical practice?
FROM CLINICAL TRIALS TO CLINICAL PRACTICE: TRANSLATING EPILEPSY RESEARCH INTO PATIENT CARE Interview with Jacqueline A. French, MD Dr Jacqueline A. French is a Professor in the Department of Neurology
More informationPregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)
Pregnancy General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) In all women of child bearing potential Always discuss the possibility of pregnancy; half of all pregnancies are unplanned
More informationLacosamide (Vimpat) for partial-onset epilepsy monotherapy. December 2011
Lacosamide (Vimpat) for partial-onset epilepsy monotherapy This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationSummary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT Larig 100 mg Dispersible Tablets Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each dispersible tablet contains 100mg Lamotrigine. Excipients
More informationFDA Approves Carnexiv (carbamazepine) injection as Intravenous Short-Term Replacement Therapy for Certain Seizure Types
FOR IMMEDIATE RELEASE FDA Approves Carnexiv (carbamazepine) injection as Intravenous Short-Term Replacement Therapy for Certain Seizure Types Carnexiv is the first FDA-approved intravenous carbamazepine
More informationAMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY, INC. SUBSPECIALTY CERTIFICATION EXAMINATION IN EPILEPSY MEDICINE
SUBSPECIALTY CERTIFICATION EXAMINATION IN EPILEPSY MEDICINE 2014 Content Blueprint (November 26, 2012) Number of questions: 200 I. Classification 7 9% II. Routine EEG 16 20% III. Evaluation 22 26% IV.
More informationThe epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care Issued: January 2012 guidance.nice.org.uk/cg137 NHS Evidence has accredited the process
More informationEPILEPSY DIAGNOSIS. Investigations- EEG, MRI, CT, blood tests. Appendix 1 contains a guide to questions to help with diagnosis
EPILEPSY DIAGNOSIS All adults with a recent-onset suspected seizure should be seen urgently by a specialist. The seizure type(s) and epilepsy syndrome, aetiology and co-morbidity should be determined.
More informationRECENT MAJOR CHANGES Warnings and Precautions, Hemophagocytic
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LAMICTAL safely and effectively. See full prescribing information for LAMICTAL. LAMICTAL (lamotrigine)
More informationMonitoring and Antiepileptic Drug Safety
Practice Monitoring and Antiepileptic Drug Safety L. James Willmore, MD, FAAN, FANA ABSTRACT Treatment of patients with epilepsy strives for complete seizure control without intolerable drug side effects.
More informationChapter 31-Epilepsy 1. public accountant, and has begun treatment with lamotrigine. In which of the following activities
Chapter 31-Epilepsy 1 Chapter 31. Epilepsy, Self-Assessment Questions 1. BW is a 28-year-old man recently diagnosed with partial seizures. He works as a certified public accountant, and has begun treatment
More information